Dengue tetravalent vaccine (live, attenuated) powder and solvent for solution for injection 0.5ml pre-filled syringes

Background and objectivesDengue is one of the fastest spreading arboviral infection with no specific antiviral treatment, making vaccination a significant preventive approach. Several dengue vaccines have been developed, but their efficacy, safety, and serotype-specific protection remain areas of concern. Over the past five years, new clinical data have emerged, influencing vaccine recommendations and deployment strategies. This systematic review analyses recent dengue vaccine data, assessing their effectiveness, and safety profiles.MethodsData was taken from three different databases i.e. PubMed, Cochrane and google scholar from last five years (2020-2025) by using the specific search terms. Filters were applied to extract the studies relevant to our analysis. Data was analysed and forest plots were made for proper understanding of vaccine efficacy and safety data of vaccines.Results14 studies are included in the study and our systematic review study on dengue vaccines revealed TAK-003 and TV005 with highest protection rates in their respective settings. Safety profiles varied: TAK-003 and CYD-TDV reduced serious events, whereas TV005 was associated with heightened reactogenicity.ConclusionThis review provides a systematic review of the dengue vaccines data available from the last five years highlighting significant progress in vaccine development, efficacy, and safety and TAK-003 showed the greatest efficacy against hospitalized and symptomatic Dengue patients, reducing risk by 85% (RR 0.15; 95% CI 0.07-0.33).

Abstract licence: CC BY-NC-ND